UroGen Pharma Stock Halted, Up 50% After 82.3% Response in Trial

Jun 13, 2024, 03:16 PM

UroGen Pharma's stock ($URGN) was halted after announcing unprecedented results from its ENVISION trial. The trial showed an 82.3% duration of response at 12 months for UGN-102, a potential first FDA-approved non-surgical treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Following the announcement, $URGN stock spiked 50%, with a trading volume of 5.5 million, 15 times the average daily volume.